BIOGEN INC. - COMMON STOCK
230.57
17-May-24 15:59:59
15 minutes delayed
Stocks
+0.53
+0.23%
Today's range
226.43 - 230.83
ISIN
N/A
Source
NASDAQ
-
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
22 Mar 2023 20:32:40 By Nasdaq GlobeNewswire
-
16 Mar 2023 06:30:14 By Nasdaq GlobeNewswire
-
Biogen Appoints Chuck Triano as Head of Investor Relations
14 Mar 2023 07:30:00 By Nasdaq GlobeNewswire
-
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
08 Mar 2023 07:30:00 By Nasdaq GlobeNewswire
-
27 Feb 2023 18:30:00 By Nasdaq GlobeNewswire
-
Lecanemab Receives Priority Review Status in Japan
29 Jan 2023 18:30:00 By Nasdaq GlobeNewswire
-
26 Jan 2023 18:30:00 By Nasdaq GlobeNewswire
-
Biogen Names Priya Singhal as Executive Vice President, Head of Development
05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire
-
04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire
-
19 Dec 2022 07:30:00 By Nasdaq GlobeNewswire
-
09 Dec 2022 07:30:00 By Nasdaq GlobeNewswire
-
05 Dec 2022 07:30:00 By Nasdaq GlobeNewswire
-
Biogen Names Christopher Viehbacher President and Chief Executive Officer
10 Nov 2022 07:30:01 By Nasdaq GlobeNewswire
-
26 Oct 2022 06:05:00 By Nasdaq GlobeNewswire
-
26 Oct 2022 06:02:00 By Nasdaq GlobeNewswire
-
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
17 Oct 2022 07:30:10 By Nasdaq GlobeNewswire
-
30 Sep 2022 07:00:00 By Nasdaq GlobeNewswire
-
21 Sep 2022 17:15:12 By Nasdaq GlobeNewswire